-Medicare Part B and D payment for drugs
-Issues related to the repeal of the non-interference clause in Part D
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Issues related to the Pandemic and All Hazards Preparedness Innovation Act of 2019
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to drug and insulin pricing
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Duration: January 1, 2008
to
January 1, 2020
General Issues: Medicare/Medicaid , Health Issues , Budget/Appropriations , Taxation/Internal Revenue Code , Medical/Disease Research/Clinical Labs , Copyright/Patent/Trademark
Spending: about $2,300,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), U.S. Senate,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2020
FOLEY HOAG LLP terminated an engagement in which they represented Sanofi US Services, Inc. on May 3, 2020.
Original Filing: 301181851.xml
1st Quarter, 2020
In Q1, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. , earning $45,000. The report was filed on April 26, 2020.
Original Filing: 301181199.xml
Lobbying Issues
-Medicare Part B and D payment for drugs
-Issues related to the repeal of the non-interference clause in Part D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Issues related to the Pandemic and All Hazards Preparedness Innovation Act of 2019
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to drug and insulin pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2019
In Q4, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. , earning $45,000. The report was filed on Feb. 3, 2020.
Original Filing: 301131096.xml
Lobbying Issues
-Medicare Part B and D payment for drugs
-Issues related to the repeal of the non-interference clause in Part D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Issues related to the Pandemic and All Hazards Preparedness Innovation Act of 2019
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to drug and insulin pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2019
In Q3, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. , earning $45,000. The report was filed on Oct. 31, 2019.
Original Filing: 301080628.xml
Lobbying Issues
-Medicare Part B and D payment for drugs
-Issues related to the repeal of the non-interference clause in Part D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Issues related to the Pandemic and All Hazards Preparedness Innovation Act of 2019
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to drug and insulin pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2019
In Q2, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. , earning $45,000. The report was filed on Aug. 6, 2019.
Original Filing: 301060722.xml
Lobbying Issues
-Medicare Part B and D payment for drugs
-Issues related to the repeal of the non-interference clause in Part D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417)
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to drug and insulin pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2019
In Q1, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. , earning $45,000. The report was filed on May 3, 2019.
Original Filing: 301040142.xml
Lobbying Issues
-Medicare Part B and D payment for drugs
-Issues related to the repeal of the non-interference clause in Part D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417)
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to Right to Try
-Issues related to drug and insulin pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. , earning $45,000. The report was filed on Jan. 23, 2019.
Original Filing: 301018544.xml
Lobbying Issues
-Medicare Part B and D payment for drugs
-Issues related to the repeal of the non-interference clause in Part D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417)
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to Right to Try
-Issues related to drug and insulin pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018"
-Issues related to H.R. 1892 "Bipartisan Budget Act of 2018"
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2018
In Q3, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. , earning $45,000. The report was filed on Oct. 25, 2018.
Original Filing: 300999318.xml
Lobbying Issues
-Medicare Part B and D payment for drugs
-Issues related to the repeal of the non-interference clause in Part D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417)
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to Right to Try
-Issues related to drug and insulin pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018"
-Issues related to H.R. 1892 "Bipartisan Budget Act of 2018"
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2018
FOLEY HOAG LLP amended a lobbying report for representation of Sanofi US Services, Inc. in Q22018 on July 20, 2018.
Original Filing: 300976661.xml
Lobbying Issues
-Medicare Part B and D payment for drugs
-Issues related to the repeal of the non-interference clause in Part D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417)
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to Right to Try
-Issues related to drug and insulin pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018"
-Issues related to H.R. 1892 "Bipartisan Budget Act of 2018"
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2018
In Q2, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. , earning $45,000. The report was filed on July 20, 2018.
Original Filing: 300976588.xml
Lobbying Issues
-Medicare Part B and D payment for drugs
-Issues relating to IPAB in S. 251 "Protecting Medicare from Executive Action of 2017"
-Issues related to the repeal of the non-interference clause in Part D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148)
-Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152)
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417)
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to Right to Try
-Issues related to drug and insulin pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018"
-Issues related to H.R. 1892 "Bipartisan Budget Act of 2018"
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2018
In Q1, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. , earning $45,000. The report was filed on April 24, 2018.
Original Filing: 300959010.xml
Lobbying Issues
-Medicare Part B and D payment for drugs
-Issues relating to IPAB in S. 251 "Protecting Medicare from Executive Action of 2017"
-Issues related to the repeal of the non-interference clause in Part D
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148)
-Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152)
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development
-Implementation of 21st Century Cures (P.L. 114-255)
-Issues related to pandemic and seasonal influenza vaccine development
-Reauthorization of Pandemic and All Hazards Preparedness (P.L. 109-417)
-Issues related to over-the-counter drug and cosmetic reform legislation
-Issues related to Right to Try
-Issues related to drug and insulin pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Issues related to H.R. 1625: "Consolidated Appropriations Act of 2018"
-Issues related to H.R. 1892 "Bipartisan Budget Act of 2018"
-Issues related to National Institute of Health funding
-Issues related to Biomedical Advanced Research and Development Authority
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
-Issues related to H.R. 4996: "Vaccine Access Improvement Act of 2018"
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2017
In Q4, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. , earning $45,000. The report was filed on Jan. 22, 2018.
Original Filing: 300932566.xml
Lobbying Issues
-Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148).
-Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152).
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development.
-Implementation of 21st Century Cures (P.L. 114-255).
-Issues related to pandemic and seasonal influenza vaccine development.
-Issues related to over-the-counter drug and cosmetic reform legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2017
In Q3, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. (formerly known as Sanofi Genzyme) , earning $30,000. The report was filed on Nov. 1, 2017.
Original Filing: 300918534.xml
Lobbying Issues
-Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148).
-Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152).
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development.
-Implementation of H.R. 6 - 21st Century Cures (P.L. 114-255).
-S.2013 Trickett Wendler Right to Try Act of 2017.
-H.R. 2430 and S. 932, FDA Reauthorization Act.
-Issues related to Zika vaccine development.
-Issues related to over-the-counter drug and cosmetic reform legislation.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, FOLEY HOAG LLP lobbied for Sanofi US Services, Inc. (formerly known as Sanofi Genzyme) , earning $30,000. The report was filed on July 19, 2017.
Original Filing: 300891085.xml
Lobbying Issues
-Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148).
-Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152).
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development.
-H.R. 6 - 21st Century Cures (P.L. 114-255).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2017
In Q1, FOLEY HOAG LLP lobbied for SANOFI GENZYME (formerly known as Genzyme) , earning $30,000. The report was filed on April 20, 2017.
Original Filing: 300875506.xml
Lobbying Issues
-Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
-Implementation of the Affordable Care Act of 2010 (P.L. 111-148).
-Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152).
-Implementation of Orphan Drug Act of 1983 (P.L. 97-414) and orphan drug development.
-H.R. 6 - 21st Century Cures (P.L. 114-255).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2016
In Q4, FOLEY HOAG LLP lobbied for SANOFI GENZYME (formerly known as Genzyme) , earning $30,000. The report was filed on Jan. 23, 2017.
Original Filing: 300857090.xml
Lobbying Issues
- Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
- Implementation of the Affordable Care Act of 2010 (P.L. 111-148).
- Implementation of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152).
- Implementation of Orphan Drug Act of 1983 (P.L 97-414) and orphan drug development.
- H.R. 6 - 21st Century Cures (P.L. 114-255).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, FOLEY HOAG LLP lobbied for SANOFI GENZYME (formerly known as Genzyme) , earning $30,000. The report was filed on Oct. 19, 2016.
Original Filing: 300833100.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Implementation of the "Affordable Care Act of 2010 (P.L. 111-148), and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) (Biosimilars).
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
Implementation of Orphan Drug Act and orphan drug development.
House Committee on Energy & Commerce 21st Century Cures initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
In Q2, FOLEY HOAG LLP lobbied for SANOFI GENZYME (formerly known as Genzyme) , earning $30,000. The report was filed on July 15, 2016.
Original Filing: 300810410.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Implementation of the "Affordable Care Act of 2010 (P.L. 111-148), and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) (Biosimilars).
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
Implementation of Orphan Drug Act and orphan drug development.
House Committee on Energy & Commerce 21st Century Cures initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2016
FOLEY HOAG LLP amended a lobbying report for representation of SANOFI GENZYME (formerly known as Genzyme) in Q12016 on April 20, 2016.
Original Filing: 300800182.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Implementation of the "Affordable Care Act of 2010 (P.L. 111-148), and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) (Biosimilars).
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
Implementation of Orphan Drug Act and orphan drug development.
House Committee on Energy & Commerce 21st Century Cures initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2016
In Q1, FOLEY HOAG LLP lobbied for SANOFI GENZYME , earning $30,000. The report was filed on April 19, 2016.
Original Filing: 300796843.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Implementation of the "Affordable Care Act of 2010 (P.L. 111-148), and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) (Biosimilars).
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
Implementation of Orphan Drug Act and orphan drug development.
House Committee on Energy & Commerce 21st Century Cures initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2015
In Q4, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on Jan. 20, 2016.
Original Filing: 300784117.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Implementation of the "Affordable Care Act of 2010 (P.L. 111-148), and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) (Biosimilars).
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
Implementation of Orphan Drug Act and orphan drug development.
House Committee on Energy & Commerce 21st Century Cures initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2015
In Q3, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on Oct. 16, 2015.
Original Filing: 300754700.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Implementation of the "Affordable Care Act of 2010 (P.L. 111-148), and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) (Biosimilars).
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
Implementation of Orphan Drug Act and orphan drug development.
House Committee on Energy & Commerce 21st Century Cures initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2015
In Q2, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on July 20, 2015.
Original Filing: 300743206.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Implementation of the "Affordable Care Act of 2010 (P.L. 111-148), and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) (Biosimilars).
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
Regulation of innovative biological products for neurodegenerative diseases.
Implementation of Orphan Drug Act and orphan drug development.
House Committee on Energy & Commerce 21st Century Cures initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2015
In Q1, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on April 21, 2015.
Original Filing: 300728046.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Implementation of the "Affordable Care Act of 2010 (P.L. 111-148), and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) (Biosimilars).
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
Regulation of innovative biological products for neurodegenerative diseases.
Implementation of Orphan Drug Act and orphan drug development.
House Committee on Energy & Commerce 21st Century Cures initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2014
In Q4, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on Jan. 21, 2015.
Original Filing: 300708449.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Implementation of the "Affordable Care Act of 2010 (P.L. 111-148), and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152)(Biosimilars).
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
Regulation of innovative biological products for neurodegenerative diseases.
House Committee on Energy & Commerce 21st Century Cures initiative.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2014
In Q3, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on Oct. 20, 2014.
Original Filing: 300683994.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Implementation of the "Affordable Care Act of 2010 (P.L. 111-148), and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152) (Biosimilars); (Independent Payment Advisory Board "IPAB".
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
Regulation of innovative biological products for neurodegenerative diseases.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2014
In Q2, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on July 18, 2014.
Original Filing: 300662276.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding Americas Pharmaceuticals Act of 2013
Regulation of innovative biological products for neurodegenerative diseases.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2014
FOLEY HOAG LLP amended a lobbying report for representation of GENZYME in Q12014 on April 24, 2014.
Original Filing: 300650056.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding Americas Pharmaceuticals Act of 2013
S. 959, Pharmaceutical Compounding Quality and Accountability Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2014
In Q1, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on April 18, 2014.
Original Filing: 300640803.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding Americas Pharmaceuticals Act of 2013
S. 959, Pharmaceutical Compounding Quality and Accountability Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
FOLEY HOAG LLP amended a lobbying report for representation of GENZYME in Q42013 on April 18, 2014.
Original Filing: 300640779.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding Americas Pharmaceuticals Act of 2013
S. 959, Pharmaceutical Compounding Quality and Accountability Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on Jan. 20, 2014.
Original Filing: 300620963.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding Americas Pharmaceuticals Act of 2013
S. 959, Pharmaceutical Compounding Quality and Accountability Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on Oct. 18, 2013.
Original Filing: 300600132.xml
Lobbying Issues
Medicare Part B payment for drugs.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding Americas Pharmaceuticals Act of 2013
S. 959, Pharmaceutical Compounding Quality and Accountability Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2013
In Q2, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on July 22, 2013.
Original Filing: 300582291.xml
Lobbying Issues
Medicare Part D Prescription Drug Benefit; Medicare coverage policy for chronic renal disease; Medicare Part B payment and coverage of dialysis products; Congressional deficit reduction negotiations, and implementation of the Budget Control Act of 2011 (P.L. 112-25)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144).
S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding Americas Pharmaceuticals Act of 2013
S. 959, Pharmaceutical Compounding Quality and Accountability Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2013
In Q1, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on April 22, 2013.
Original Filing: 300561947.xml
Lobbying Issues
Medicare Part D Prescription Drug Benefit; Medicare coverage policy for chronic renal disease; Medicare Part B payment and coverage of dialysis products; Congressional deficit reduction negotiations, and implementation of the Budget Control Act of 2011 (P.L. 112-25)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Implementation of P.L. 111-148, Patient Protection and Affordable Care Act and Implementation of P.L. 111-152, Health Care and Education Reconciliation Act (Biosimilars); (Independent Payment Advisory Board "IPAB")
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2012
In Q4, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on Jan. 18, 2013.
Original Filing: 300535026.xml
Lobbying Issues
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care Eduction Reconciliation Act of 2010 (Pub. L. 111-152)(Biosimilars); Budget Control Act of 2011 (P.L. 112-25).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on Oct. 22, 2012.
Original Filing: 300518477.xml
Lobbying Issues
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care Eduction Reconciliation Act of 2010 (Pub. L. 111-152)(Biosimilars); Budget Control Act of 2011 (P.L. 112-25).
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on July 20, 2012.
Original Filing: 300497148.xml
Lobbying Issues
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care Eduction Reconciliation Act of 2010 (Pub. L. 111-152)(Biosimilars); Budget Control Act of 2011 (P.L. 112-25).
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on April 20, 2012.
Original Filing: 300469490.xml
Lobbying Issues
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care Eduction Reconciliation Act of 2010 (Pub. L. 111-152)(Biosimilars); Budget Control Act of 2011 (P.L. 112-25).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, FOLEY HOAG LLP lobbied for GENZYME , earning $45,000. The report was filed on Jan. 20, 2012.
Original Filing: 300452873.xml
Lobbying Issues
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010
(Pub. L. 111-152)(Biosimilars); Budget Control Act of 2011(P.L. 112-25).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, FOLEY HOAG LLP lobbied for GENZYME , earning $30,000. The report was filed on Oct. 20, 2011.
Original Filing: 300429685.xml
Lobbying Issues
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010
(Pub. L. 111-152)(Biosimilars)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, FOLEY HOAG LLP lobbied for GENZYME , earning $45,000. The report was filed on July 20, 2011.
Original Filing: 300405607.xml
Lobbying Issues
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010
(Pub. L. 111-152)(Biosimilars)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, FOLEY HOAG LLP lobbied for GENZYME , earning $45,000. The report was filed on April 20, 2011.
Original Filing: 300380065.xml
Lobbying Issues
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010
(Pub. L. 111-152)(Biosimilars)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, FOLEY HOAG LLP lobbied for GENZYME , earning $60,000. The report was filed on Jan. 20, 2011.
Original Filing: 300354810.xml
Lobbying Issues
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010
(Pub. L. 111-152); American Jobs and Closing Tax Loopholes Act of 2010 (H.R. 4213)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, FOLEY HOAG LLP lobbied for GENZYME , earning $65,000. The report was filed on Oct. 20, 2010.
Original Filing: 300329382.xml
Lobbying Issues
Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010
(Pub. L. 111-152); American Jobs and Closing Tax Loopholes Act of 2010 (H.R. 4213)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, FOLEY HOAG LLP lobbied for GENZYME , earning $75,000. The report was filed on July 20, 2010.
Original Filing: 300299341.xml
Lobbying Issues
Patient Protection and Affordable Care Act (P.L. 111-148)
Health Care and Education Reconciliation Act (P.L. 111-152)
American Jobs and Closing Tax Loopholes Act of 2010 (H. R. 4213)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Medicare and Medicaid payment for Prescription drugs
Patient Protection and Affordable Care Act (P.L. 111-148)
Health Care and Education Reconciliation Act (P.L. 111-152)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
1st Quarter, 2010
In Q1, FOLEY HOAG LLP lobbied for GENZYME , earning $75,000. The report was filed on April 20, 2010.
Original Filing: 300275689.xml
Lobbying Issues
Patient Protection and Affordable Care Act (H.R. 3590);
Health Care and Education Affordability Reconciliation Act (H.R. 4872)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Medicare and Medicaid payment for Prescription drugs
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
4th Quarter, 2009
In Q4, FOLEY HOAG LLP lobbied for GENZYME , earning $90,000. The report was filed on Jan. 20, 2010.
Original Filing: 300247839.xml
Lobbying Issues
Patient Protection and Affordable Care Act - H.R.3590
Affordable Health Care for America Act - HR 3962
Follow-on Biologics - H.R.1427, H.R.1548
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Medicare and Medicaid payment for Prescription drugs
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
3rd Quarter, 2009
In Q3, FOLEY HOAG LLP lobbied for GENZYME , earning $90,000. The report was filed on Oct. 20, 2009.
Original Filing: 300217237.xml
Lobbying Issues
S.___ Affordable Healthy Choices Act; Americas Affordable Health Choices Act H.R.3200
Follow-on Biologics- H.R.1427, H.R.1548
Physician Payments Sunshine Act- S.301
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
2nd Quarter, 2009
FOLEY HOAG LLP amended a lobbying report for representation of GENZYME in Q22009 on Nov. 10, 2011.
Original Filing: 300432446.xml
Lobbying Issues
Follow-on Biologics- H.R. 1427, H.R. 1548, S1695
Physician Payments Sunshine Act- S.301
Health Care Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Part B Medicare Reimbursement
Medicare Improvements for Patients and Providers Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
2nd Quarter, 2009
In Q2, FOLEY HOAG LLP lobbied for GENZYME , earning $90,000. The report was filed on July 20, 2009.
Original Filing: 300193964.xml
Lobbying Issues
Follow-on Biologics- H.R. 1427, H.R. 1548, S1695
Physician Payments Sunshine Act- S.301
Health Care Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Part B Medicare Reimbursement
Medicare Improvements for Patients and Providers Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
1st Quarter, 2009
FOLEY HOAG LLP amended a lobbying report for representation of GENZYME in Q12009 on Nov. 10, 2011.
Original Filing: 300432477.xml
Lobbying Issues
Follow-on Biologics- HR 1427, HR 1548
Physician Payments Sunshine Act- S301
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Part B Medicare Reimbursement
Medicare Improvements for Patients and Providers Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Patent Reform- S515, HR 1260
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2009
FOLEY HOAG LLP amended a lobbying report for representation of GENZYME in Q12009 on July 23, 2010.
Original Filing: 300304931.xml
Lobbying Issues
Follow-on Biologics- HR 1427, HR 1548
Physician Payments Sunshine Act- S301
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Part B Medicare Reimbursement
Medicare Improvements for Patients and Providers Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Patent Reform- S515, HR 1260
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2009
FOLEY HOAG LLP amended a lobbying report for representation of GENZYME in Q12009 on July 23, 2010.
Original Filing: 300304946.xml
Lobbying Issues
Follow-on Biologics- HR 1427, HR 1548
Physician Payments Sunshine Act- S301
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Part B Medicare Reimbursement
Medicare Improvements for Patients and Providers Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Patent Reform- S515, HR 1260
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2009
In Q1, FOLEY HOAG LLP lobbied for GENZYME , earning $90,000. The report was filed on April 21, 2009.
Original Filing: 300165837.xml
Lobbying Issues
Follow-on Biologics- HR 1427, HR 1548
Physician Payments Sunshine Act- S301
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Part B Medicare Reimbursement
Medicare Improvements for Patients and Providers Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Patent Reform- S515, HR 1260
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2008
FOLEY HOAG LLP amended a lobbying report for representation of GENZYME in Q42008 on Jan. 20, 2009.
Original Filing: 300128278.xml
Lobbying Issues
Follow-on Biologics legislation - S 1695, S 623, HR 1038, HR 1956
Food and Drug Globalization Act - S 3409, HR 3610
Physician Payments Sunshine Act - S 2029
Mental health parity legislation - S 558, HR 1424
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Part B Medicare Reimbursement
Medicare Improvements for Patients and Providers Act - HR 6331
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Patent Reform Act of 2007 - S 1145, HR 1908
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2008
In Q4, FOLEY HOAG LLP lobbied for GENZYME , earning $90,000. The report was filed on Jan. 15, 2009.
Original Filing: 300120026.xml
Lobbying Issues
Follow-on Biologics legislation - S 1695, S 623, HR 1038, HR 1956
Food and Drug Globalization Act - S 3409, HR 3610
Physician Payments Sunshine Act - S 2029
Mental health parity legislation - S 558, HR 1424
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Part B Medicare Reimbursement
Medicare Improvements for Patients and Providers Act - HR 6331
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Patent Reform Act of 2007 - S 1145, HR 1908
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2008
In Q3, FOLEY HOAG LLP lobbied for GENZYME , earning $90,000. The report was filed on Oct. 20, 2008.
Original Filing: 300107612.xml
Lobbying Issues
Follow-on Biologics legislation - S 1695, S 623, HR 1038, HR 1956
Food and Drug Globalization Act - S 3409, HR 3610
Physician Payments Sunshine Act - S 2029
Mental health parity legislation - S 558, HR 1424
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Part B Medicare Reimbursement
Medicare Improvements for Patients and Providers Act - HR 6331
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Patent Reform Act of 2007 - S 1145, HR 1908
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2008
In Q2, FOLEY HOAG LLP lobbied for GENZYME , earning $90,000. The report was filed on July 21, 2008.
Original Filing: 300081113.xml
Lobbying Issues
Follow-on Biologics legislation - S 1695, S 623, HR 1038, HR 1956
Food and Drug Globalization Act - S ___, HR ___
Physician Payments Sunshine Act - S 2029
Mental health parity legislation - S 558, HR 1424
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Part B Medicare Reimbursement
Medicare Improvements for Patients and Providers Act - HR 6331
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Patent Reform Act of 2007 - S 1145, HR 1908
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2008
In Q1, FOLEY HOAG LLP lobbied for GENZYME , earning $90,000. The report was filed on April 18, 2008.
Original Filing: 300045663.xml
Lobbying Issues
Follow-on Biologics legislation: S 1695, S 623, HR 1038, HR 1956
Food and Drug legislation: S 1082, HR 2900
Physician Payments Sunshine Act, S 2029
Mental health parity legislation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Part B Medicare Reimbursement
CHAMP Act, HR 3162
SCHIP Extension Act, S 2499
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
Patent Reform Act of 2007: S 1145, HR 1908
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate